Pakistan: A study published in Medicine has found that semaglutide was associated with more than twice the likelihood of resolving metabolic dysfunction-associated steatohepatitis (MASH) compared with placebo. While semaglutide effectively improved liver inflammation, it did not consistently improve or worsen liver fibrosis, highlighting a gap in reversing established scarring. Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), and its progressive inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), are among the leading causes of chronic liver disease worldwide. The analysis showed that semaglutide more than doubled the likelihood of MASH resolution without worsening liver fibrosis compared with placebo. Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.